Subscribe Now

Amyrt's AP103 Receives the US FDA's Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)

Senior Editor

Dec 28, 2020

Regulatory

Amyrt's AP103 Receives the US FDA's Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)

Shots:

The US FDA has granted orphan drug designation for AP103 for the treatment of DEB
Amyrt licensed a pre-clinical gene – therapy platform technology to treat patients with DEB- a subset of EB also applicable for genetic disorders in Mar 2018
AP103 is based on a novel polymer-based topical delivery platform and offers potential advantages in the gene therapy field also used in other genetic skin conditions

Ref: GlobeNewswire | Image: Twitter

Click here to read the full press release

Tags

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Comments

Related News/Articles

Amryt Receives CHMP Positive Opinion of Filsuvez for the Treatment of Dystrophic and Junctional EB

Amryt Receives CHMP Positive Opinion of Filsuvez for the Treatment of Dystrophic and Junctional EB

April 25, 2022

Amryt Reports Results of Mycapssa in P-III (MPOWERED) Study for the Treatment of Acromegaly

Amryt Reports Results of Mycapssa in P-III (MPOWERED) Study for the Treatment of Acromegaly

January 12, 2022

Amryt Publishes Results of Mycapssa in P-III (MPOWERED) Trial for the Treatment of Acromegaly in The Lancet Diabetes & Endocrinology

Amryt Publishes Results of Mycapssa in P-III (MPOWERED) Trial for the Treatment of Acromegaly in The Lancet Diabetes & Endocrinology

January 5, 2022

Amryt Reports NDA Submission for Oleogel-S10 (filsuvez) to Treat Cutaneous Manifestations of Junctional and Dystrophic Epidermolysis Bullosa

Amryt Reports NDA Submission for Oleogel-S10 (filsuvez) to Treat Cutaneous Manifestations of Junctional and Dystrophic Epidermolysis Bullosa

April 1, 2021

Amyrt's AP103 Receives the US FDA's Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)

Amyrt's AP103 Receives the US FDA's Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)

December 28, 2020

InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC

InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC

November 21, 2024

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

November 21, 2024

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

November 21, 2024

Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

November 21, 2024

Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy

Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy

November 20, 2024

X

Liked our insights or summarized news?

Subscribe to our Daily/Weekly newsletter

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us